Dr. David B. Moore, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of Iowa, Rj & L Carver College of Medicine (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 408
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: University of Iowa, Rj & L Carver College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
IA license 33493
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mary Greeley Medical Center Ames, IA
Medical groups
- Mcfarland Clinic PC (363 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 408
- Services billed
- 17,718
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 18,316 | 38 |
| Established patient office or other outpatient visit, 30-39 minutes | 261 | 189 |
| Injection, baclofen, 10 mg | 179 | 14 |
| Established patient office or other outpatient visit, 20-29 minutes | 108 | 97 |
| Established patient office or other outpatient visit, 10-19 minutes | 92 | 46 |
| New patient office or other outpatient visit, 60-74 minutes | 55 | 55 |
| Established patient office or other outpatient visit, 40-54 minutes | 49 | 44 |
| Insertion of needle into vein for collection of blood sample | 37 | 30 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 35 | 14 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 34 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Lamotrigine Other prescribers in Ames, IA | 501 |
| Levetiracetam Other prescribers in Ames, IA | 424 |
| Lacosamide Other prescribers in Ames, IA | 408 |
| Divalproex Sodium Er (divalproex sodium) Other prescribers in Ames, IA | 242 |
| Clobazam | 172 |
| Divalproex Sodium Other prescribers in Ames, IA | 171 |
| Clonazepam Other prescribers in Ames, IA | 145 |
| Rufinamide | 120 |
| Zonisamide Other prescribers in Ames, IA | 103 |
| Primidone Other prescribers in Ames, IA | 103 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 23 payments worth $528 in total to this clinician.
| AbbVie Inc. | $206 |
|---|---|
| Teva Pharmaceuticals USA, Inc. | $68.10 |
| Biogen, Inc. | $57.94 |
| Ceribell, Inc. | $50.28 |
| Livanova USA, Inc. | $48.40 |
| Genentech USA, Inc. | $39.11 |
| Lundbeck LLC | $26.74 |
| Sk Life Science, Inc. | $16.96 |
| Food and Beverage | $528 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 3 companies. The companies reported $245,751 in research payments for these studies, mostly to the institutions running them.
- A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
H. Lundbeck A S · Completed · NCT06323928 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. · Active, not recruiting · NCT06417775 - Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
AbbVie Inc. · Enrolling by invitation · NCT05127954 - Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc. · Recruiting · NCT05125302 - M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. - Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc. - Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc. - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. - A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063)
Celgene Corporation - M21-307 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.